Lista de obras -

Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study

artículo científico publicado en 2017

Carcinosarcoma of the prostate: case report with molecular and histological characterization

artículo científico publicado en 2018

Cell-free DNA as a diagnostic marker for cancer: current insights

artículo científico publicado en 2016

Circulating AR copy number and outcome to enzalutamide in docetaxel-treated metastatic castration-resistant prostate cancer.

artículo científico publicado en 2016

Circulating androgen receptor combined with 18F-fluorocholine PET/CT metabolic activity and outcome to androgen receptor signalling-directed therapies in castration-resistant prostate cancer

artículo científico publicado en 2017

Epigenetic Characterization of Cell-Free DNA

artículo científico publicado en 2019

GSTP1 Methylation and Protein Expression in Prostate Cancer: Diagnostic Implications

artículo científico publicado en 2016

GSTP1 methylation in cancer: a liquid biopsy biomarker?

artículo científico publicado en 2018

Immune System and DNA Repair Defects in Ovarian Cancer: Implications for Locoregional Approaches

artículo científico publicado en 2019

Impact of Candidate Genetic Polymorphisms in Prostate Cancer: An Overview.

artículo científico publicado en 2015

Methylation pattern analysis in prostate cancer tissue: identification of biomarkers using an MS-MLPA approach.

artículo científico publicado en 2016

Oxaliplatin plus leucovorin and 5-fluorouracil (FOLFOX-4) as a salvage chemotherapy in heavily-pretreated platinum-resistant ovarian cancer

artículo científico publicado en 2018

Plasma AR and abiraterone-resistant prostate cancer.

artículo científico publicado en 2015

Plasma AR status and cabazitaxel in heavily treated metastatic castration-resistant prostate cancer

artículo científico publicado en 2019

Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer

artículo científico publicado en 2018

Plasma Androgen Receptor in Prostate Cancer

artículo científico publicado en 2019

Plasma androgen receptor and serum chromogranin A in advanced prostate cancer

artículo científico publicado en 2018

Re: Niven Mehra, David Dolling, Semini Sumanasuriya, et al. Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIRSTANA and PROSELICA). Eur Urol 2018;74:2

artículo científico publicado en 2018

Reclassification of good-risk seminoma: prognostic factors, novel biomarkers and implications for clinical management

artículo científico publicado en 2019

Serum and Plasma Copy Number Detection Using Real-time PCR.

artículo científico publicado en 2017

Testosterone levels and androgen receptor copy number variations in castration-resistant prostate cancer treated with abiraterone or enzalutamide

scientific article published on 01 August 2019

The potential use of urine cell free DNA as a marker for cancer.

artículo científico publicado en 2016

Urine Cell-Free DNA Integrity Analysis for Early Detection of Prostate Cancer Patients

artículo científico publicado en 2015

Urothelial Cancer: Inflammatory Mediators and Implications for Immunotherapy.

artículo científico publicado en 2016

Lista de obras de

Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study

Carcinosarcoma of the prostate: case report with molecular and histological characterization

Cell-free DNA as a diagnostic marker for cancer: current insights

Circulating AR copy number and outcome to enzalutamide in docetaxel-treated metastatic castration-resistant prostate cancer.

Circulating androgen receptor combined with 18F-fluorocholine PET/CT metabolic activity and outcome to androgen receptor signalling-directed therapies in castration-resistant prostate cancer

Epigenetic Characterization of Cell-Free DNA

GSTP1 Methylation and Protein Expression in Prostate Cancer: Diagnostic Implications

GSTP1 methylation in cancer: a liquid biopsy biomarker?

Immune System and DNA Repair Defects in Ovarian Cancer: Implications for Locoregional Approaches

Impact of Candidate Genetic Polymorphisms in Prostate Cancer: An Overview.

Methylation pattern analysis in prostate cancer tissue: identification of biomarkers using an MS-MLPA approach.

Oxaliplatin plus leucovorin and 5-fluorouracil (FOLFOX-4) as a salvage chemotherapy in heavily-pretreated platinum-resistant ovarian cancer

Plasma AR and abiraterone-resistant prostate cancer.

Plasma AR status and cabazitaxel in heavily treated metastatic castration-resistant prostate cancer

Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer

Plasma Androgen Receptor in Prostate Cancer

Plasma androgen receptor and serum chromogranin A in advanced prostate cancer

Re: Niven Mehra, David Dolling, Semini Sumanasuriya, et al. Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIRSTANA and PROSELICA). Eur Urol 2018;74:2

Reclassification of good-risk seminoma: prognostic factors, novel biomarkers and implications for clinical management

Serum and Plasma Copy Number Detection Using Real-time PCR.

Testosterone levels and androgen receptor copy number variations in castration-resistant prostate cancer treated with abiraterone or enzalutamide

The potential use of urine cell free DNA as a marker for cancer.

Urine Cell-Free DNA Integrity Analysis for Early Detection of Prostate Cancer Patients

Urothelial Cancer: Inflammatory Mediators and Implications for Immunotherapy.